Jennifer Low

Jennifer Low joined 23andMe in 2018 as Head of Therapeutics Development. She oversees the transition of potential therapeutics from 23andMe's research laboratories into clinical development studies.

Jennifer has considerable drug development experience and has most recently worked as a consultant and advisor to biotech CEOs and investors on their drug development strategies. She has been the Chief Medical Officer and Executive Vice President of Research and Development at Loxo Oncology where she oversaw the clinical development of Vitrakvi (Trk inhibitor). Prior to that she was a Senior Group Director at Genentech, a member of the Roche Group, where she oversaw the Erivedge (hedgehog), Zelboraf (b-RAF), and Cotellic (mek) clinical development programs among many others.

She received her undergraduate degree from Caltech, her MD and PhD degrees from Georgetown, and completed her internal medicine residency at the University of California Davis, her medical oncology fellowship at the National Cancer Institute, and was a Senior Investigator at the Cancer Therapeutics Evaluation Program at NCI and an attending physician in breast cancer at the National Institutes of Health and the National Naval Medical Center in Bethesda. She has co-authored papers appearing in the New England Journal of Medicine, Science, Cancer Discovery, Journal of Clinical Oncology, and Nature Reviews Cancer.